Anbet Pharmaceutical

Anbet Pharmaceutical is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses primarily on oncology, metabolic diseases, and inflammatory disorders, leveraging a structure-based drug design platform to target challenging biological pathways. Its lead programs include inhibitors targeting the RAS/MAPK pathway, such as KRAS G12C and SOS1, aimed at treating various solid tumors. Anbet aims to address significant unmet medical needs through precision medicine and efficient drug development processes. The company is supported by a team of experienced scientists and backed by leading venture capital investors. Its research facilities are located in the Zhangjiang Hi-Tech Park, a major hub for biopharmaceutical innovation.